ReviewJournal of hematology & oncology2010
The potential benefits of low-molecular-weight heparins in cancer patients.
Review in Journal of hematology & oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Case Report: Unique presentation of iliac vein rupture in an elderly female patient: a multidisciplinary approach to diagnosis and management.Frontiers in surgery · 2026Article
- Non-Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer.Oral diseases · 2025Article
- Systemic embolization due to non-bacterial thrombotic endocarditis: An autopsy case report and mini review of the literature.SAGE open medical case reports · 2024Article
- The role of coagulome in the tumor immune microenvironment.Advanced drug delivery reviews · 2023Review
- Perfluorocarbons: A perspective of theranostic applications and challenges.Frontiers in bioengineering and biotechnology · 2023Review
- Association between short-term heart rate variability and blood coagulation in patients with breast cancer.Scientific reports · 2021Article
- Description of anti-Xa monitoring practices during low molecular weight heparin use.Journal of thrombosis and thrombolysis · 2019Article
- Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.Journal of thrombosis and haemostasis : JTH · 2018Article
- Thromboprophylaxis in Head and Neck Microvascular Reconstruction.Craniomaxillofacial trauma & reconstruction · 2018Review
- Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice.Frontiers in neurology · 2016Review
- Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin.Biotechnology journal · 2015Article
- Novel antidotes for target specific oral anticoagulants.Experimental hematology & oncology · 2015Review
- The potential of heparanase as a therapeutic target in cancer.Biochemical pharmacology · 2014Article
- Cancer-associated thrombosis: an overview.Clinical Medicine Insights. Oncology · 2014Review
- Breast cancer as an acquired thrombophilic state.Journal of breast cancer · 2012Article
- Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.Investigational new drugs · 2012Article
- Novel agents for anti-platelet therapy.Journal of hematology & oncology · 2011Review
- Exploiting the tumor microenvironment for theranostic imaging.NMR in biomedicine · 2011Review
- Stroke and Cancer- A Complicated Relationship.Journal of neurology & translational neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients are at increased risk of venous thromboembolism due to a range of factors directly related to their disease and its treatment. Given the high incidence of post-surgical venous thromboembolism in cancer patients and the poor outcomes associated with its development, thromboprophylaxis is warranted. A number of evidence-based guidelines delineate anticoagulation regimens for venous thromboembolism treatment, primary and secondary prophylaxis, and long-term anticoagulation in cancer patients. However, many give equal weight to several different drugs and do not make specific recommendations regarding duration of therapy. In terms of their efficacy and safety profiles, practicality of use, and cost-effectiveness the low-molecular-weight heparins are at least comparable to, and offer several advantages over, other available antithrombotics in cancer patients. In addition, data are emerging that the antithrombotics, and particularly low-molecular-weight heparins, may exert an antitumor effect which could contribute to improved survival in cancer patients when given for long-term prophylaxis. Such findings reinforce the importance of thromboprophylaxis with low-molecular-weight heparin in cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.